Experiment

Published Papers

 

Since founding Rational Therapeutics (now Nagourney Cancer Institute) over 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD) functional profiling assay, general cancer research, and the effectiveness of new drugs and combinations.

We have selected our most recent and most prominent papers to make available for download on this site. Click on the image or title in the section below to see each published paper.

Our most recent paper (see below) released March 2019 reported that a drug commonly used to treat kidney and liver cancer was discovered effective for breast cancer, which may open new drug therapies to patients regardless of tumor type. This means that cancer drugs can be repurposed beyond known uses.

  • Nagourney Cancer Institute Facebook
  • Nagourney Cancer Institute YouTube
  • Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients (2002)

    Phase II Trial of Gemcitabine plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Ovarian Cancer Patients (2002)
  • Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients (2000)

    Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients (2000)
  • Cisplatin Plus Gemcitabine in Previously Treated Squamous Cell Carcinoma of the Cervix: A stage II study of the Gynecologic Oncology Group (2005)

    Cisplatin Plus Gemcitabine in Previously Treated Squamous Cell Carcinoma of the Cervix: A stage II study of the Gynecologic Oncology Group (2005)
  • Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-analysis of 1,929 Cases of Leukemia and Lymphoma. (2007)

    Individualized Tumor Response (ITR) Profiling for Drug Selection in Tailored Therapy: Meta-analysis of 1,929 Cases of Leukemia and Lymphoma. (2007)
  • Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer (2008)

    Carboplatin plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer (2008)
  • Functional Profiling to Select Chemotherapy in Untreated, Advanced or Metastatic Non-small Cell Lung Cancer. (2012)

    Functional Profiling to Select Chemotherapy in Untreated, Advanced or Metastatic Non-small Cell Lung Cancer.  (2012)
  • Cost Benefit Analysis of Laboratory Directed Chemotherapy for Advanced Pancreatic Cancer in the US and Brazilian patients. (2015)

    Cost Benefit Analysis of Laboratory Directed Chemotherapy for Advanced Pancreatic Cancer in the US and Brazilian patients. (2015)
  • Ex-Vivo Programmed Cell Death and the Prediction of Response to Chemotherapy (a technical explanation of how our EVA-PCD assay works)

    Ex-Vivo Programmed Cell Death and the Prediction of Response to Chemotherapy (a technical explanation of how our EVA-PCD assay works)
  • Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis. (2013)

    Accuracy and clinical utility of in vitro cytometric profiling to personalize chemotherapy: Preliminary findings of a systematic review and meta-analysis.  (2013)
  • Efficacy of Oral Metformin in a Patient with Metastatic Adrenocortical Carcinoma: Examination of Mechanisms and Therapeutic Implications (2018)

    Efficacy of Oral Metformin in a Patient with Metastatic Adrenocortical Carcinoma: Examination of Mechanisms and Therapeutic Implications (2018)
  • New Study Finds Way to Predict Breast Cancer and Shows Cancer Is Metabolic Disorder Challenging Decades of Genomic Research (2018)

    New Study Finds Way to Predict Breast Cancer and Shows Cancer Is Metabolic Disorder Challenging Decades of Genomic Research (2018)
  • New Study Finds Drugs Can be Repurposed Beyond Known Uses (2019)

    New Study Finds Drugs Can be Repurposed Beyond Known Uses (2019)
Graph

Survival Curves

Test Tubes

Assay-Directed Therapy

Doctors

Physician

Information

Nagourney Cancer Institute
  • Facebook
  • YouTube
  • Instagram

Nagourney Cancer Insitute is managed by Rational Therapeutics, LLC.  EVA-PCD, Target Rx, and Translational Rx are registered trademarks of Rational Therapeutics.

2019 Nagourney Cancer Institute.  750 E. 29th Street, Long Beach, CA 90806   (800) 542-4357   All rights reserved.